Ascentage Pharma Group International (NASDAQ:AAPG - Get Free Report) dropped 6.2% during trading on Wednesday . The stock traded as low as $24.23 and last traded at $24.23. Approximately 6,732 shares changed hands during trading, a decline of 89% from the average daily volume of 61,093 shares. The stock had previously closed at $25.82.
Wall Street Analyst Weigh In
Separately, JPMorgan Chase & Co. began coverage on Ascentage Pharma Group International in a research note on Thursday, March 27th. They set an "overweight" rating for the company.
Get Our Latest Research Report on AAPG
Ascentage Pharma Group International Stock Down 3.7%
The company has a 50 day simple moving average of $22.70.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Ascentage Pharma Group International stock. Monashee Investment Management LLC purchased a new position in shares of Ascentage Pharma Group International (NASDAQ:AAPG - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 159,942 shares of the company's stock, valued at approximately $3,511,000. Monashee Investment Management LLC owned about 0.18% of Ascentage Pharma Group International as of its most recent SEC filing.
Ascentage Pharma Group International Company Profile
(
Get Free Report)
Ascentage Pharma Group International Co, Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.
Read More
Before you consider Ascentage Pharma Group International, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ascentage Pharma Group International wasn't on the list.
While Ascentage Pharma Group International currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
